Clinical Trial Update: A Study Assessing the Safety and Effectiveness of FEX60/PE10 Fixed Combination Tablet in Patients With Allergic Rhinitis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the safety and effectiveness of FEX60/PE10 fixed-dose combination tablet in allergic rhinitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• FEX60/PE10 Fixed Combination Tablet

Snippet

Sponsor: Sanofi | Conditions: Rhinitis Allergic | Phase 3 | Status: COMPLETED